M Jentschke1, J Kampers2, J Becker3, P Sibbertsen3, P Hillemanns2. 1. Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany. Electronic address: Jentschke.Matthias@mh-hannover.de. 2. Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany. 3. Institute of Statistics, Faculty of Economics and Management, Leibniz University Hannover, Hannover, Germany.
Abstract
INTRODUCTION: Human papillomavirus (HPV) vaccination is essential for cervical cancer prevention. However, the value of HPV vaccination in the context excisional treatment of high-grade cervical intraepithelial neoplasia (CIN 3) remains unclear. METHODS: In this meta-analysis, three retrospective and three prospective studies, three post-hoc analyses of RCTs and one cancer registry study analysing the effect of pre- or post-conization vaccination (bi- or quadrivalent vaccine) against HPV were included after a systematic review of literature. Random-effect models were prepared to evaluate the influence of vaccination on recurrent CIN 2+. RESULTS: Primary end point was CIN2+ in every study. The overall study population included 21,059 patients (3,939 vaccinations vs. 17,150 controls). The results showed a significant risk reduction for the development of new high-grade intraepithelial lesions after HPV vaccination (relative risk (RR) 0.41; 95% CI [0.27; 0.64]), independent from HPV type. Due to the heterogeneous study population multiple sub analyses regarding HPV type, age of patients, time of vaccination and follow-up were performed. Age-dependent analysis showed no differences between women under 25 years (RR 0.47 (95%-CI [0.28; 0.80]) and women of higher age (RR 0.52 (95%-CI [0.41; 0.65]). Results for HPV 16/18 positive CIN2+ showed a RR of 0.37 (95% CI [0.17; 0.80]). Overall, the number of women that would have to be vaccinated before or after conization to prevent one case of recurrent CIN 2+ (NNV) is 45.5. CONCLUSION: Meta-analysis showed a significant risk reduction of developing recurrent cervical intraepithelial neoplasia after surgical excision and HPV vaccination compared to surgical excision only.
INTRODUCTION:Human papillomavirus (HPV) vaccination is essential for cervical cancer prevention. However, the value of HPV vaccination in the context excisional treatment of high-grade cervical intraepithelial neoplasia (CIN 3) remains unclear. METHODS: In this meta-analysis, three retrospective and three prospective studies, three post-hoc analyses of RCTs and one cancer registry study analysing the effect of pre- or post-conization vaccination (bi- or quadrivalent vaccine) against HPV were included after a systematic review of literature. Random-effect models were prepared to evaluate the influence of vaccination on recurrent CIN 2+. RESULTS: Primary end point was CIN2+ in every study. The overall study population included 21,059 patients (3,939 vaccinations vs. 17,150 controls). The results showed a significant risk reduction for the development of new high-grade intraepithelial lesions after HPV vaccination (relative risk (RR) 0.41; 95% CI [0.27; 0.64]), independent from HPV type. Due to the heterogeneous study population multiple sub analyses regarding HPV type, age of patients, time of vaccination and follow-up were performed. Age-dependent analysis showed no differences between women under 25 years (RR 0.47 (95%-CI [0.28; 0.80]) and women of higher age (RR 0.52 (95%-CI [0.41; 0.65]). Results for HPV 16/18 positive CIN2+ showed a RR of 0.37 (95% CI [0.17; 0.80]). Overall, the number of women that would have to be vaccinated before or after conization to prevent one case of recurrent CIN 2+ (NNV) is 45.5. CONCLUSION: Meta-analysis showed a significant risk reduction of developing recurrent cervical intraepithelial neoplasia after surgical excision and HPV vaccination compared to surgical excision only.
Authors: Jana Smahelova; Eva Hamsikova; Viera Ludvikova; Jitka Vydrova; Joseph Traboulsi; Ondrej Vencalek; Petr Lukeš; Ruth Tachezy Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-07-01 Impact factor: 8.961
Authors: Violante Di Donato; Giuseppe Caruso; Marco Petrillo; Evangelos Kontopantelis; Innocenza Palaia; Giorgia Perniola; Francesco Plotti; Roberto Angioli; Ludovico Muzii; Pierluigi Benedetti Panici; Giorgio Bogani Journal: Vaccines (Basel) Date: 2021-04-21
Authors: Andrea Casajuana-Pérez; Mar Ramírez-Mena; Estefanía Ruipérez-Pacheco; Inés Gil-Prados; Javier García-Santos; Mónica Bellón-Del Amo; Juan J Hernández-Aguado; Jesus de la Fuente-Valero; Ignacio Zapardiel; Pluvio J Coronado-Martín Journal: Vaccines (Basel) Date: 2022-02-14
Authors: Anna Lucia Tornesello; Maria Tagliamonte; Franco M Buonaguro; Maria Lina Tornesello; Luigi Buonaguro Journal: Vaccines (Basel) Date: 2022-02-02